Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Danlong Oral Liquid (DLOL) is an approved traditional Chinese medicine (TCM) developed and manufactured by Zhejiang Kangde Pharmaceutical Group. It is primarily indicated for the treatment of respiratory conditions, specifically the acute phase of mild-to-moderate heat-asthma syndrome in bronchial asthma and chronic obstructive pulmonary disease (COPD). The herbal formulation includes *Salvia miltiorrhiza* (Danshen), *Ephedra sinica* (Mahuang), *Pheretima* (Dilong), and *Fritillaria thunbergii* (Zhejiang Beimu). According to TCM principles, the drug functions by clearing heat, relieving asthma, resolving phlegm, and dissipating blood stasis. Clinical evidence supports its use as an adjunctive or primary therapy for managing symptoms such as wheezing, cough, and sticky phlegm.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Danlong Oral Liquid.